Avellino creates new opportunities to improve health through the science and technology of genomics. Using artificial intelligence, molecular diagnostics and data aggregation, Avellino is accelerating precision health to better manage inherited diseases. AvaGen™, the world’s first genetic diagnostic tool for corneal disease, provides a universal platform for next-generation genetic sequencing across a broad spectrum of diseases. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan and the UK. To learn more about Avellino, please visit avellino.com.